Hyogo, Japan

Hidetoshi Uemura

This inventor holds 6 USPTO granted patents, plus 1 CIPO patent and 1 EPO patent. Top assignee: Fuso Pharmaceutical Industries, Ltd.. Active years: 2005-2007.




Average Co-Inventor Count = 5.0

ph-index = 2

Forward Citations = 19(Granted Patents)


Location History:

  • Itami, JP (2006)
  • Hyogo, JP (2005 - 2007)

Company Filing History:


Years Active: 2005-2007

Loading Chart...
Loading Chart...
Loading Chart...
6 patents (USPTO):Explore Patents

Title: Hidetoshi Uemura: Innovator in Serine Protease Research

Introduction

Hidetoshi Uemura is a prominent inventor based in Hyogo, Japan. He has made significant contributions to the field of biochemistry, particularly in the study of serine proteases. With a total of six patents to his name, Uemura's work has advanced our understanding of these important enzymes.

Latest Patents

Among his latest patents, Uemura has developed the Serine protease BSSP6, which includes a polynucleotide encoding human BSSP6 serine protease, along with a vector and transformed host cells containing this encoding polynucleotide. Another notable patent is the Serine protease BSSP4, which encompasses proteins with specific amino acid sequences and methods for detecting BSSP4 in specimens using antibodies.

Career Highlights

Uemura is affiliated with Fuso Pharmaceutical Industries, Ltd., where he continues to innovate and contribute to the field of pharmaceutical research. His work has been instrumental in developing new therapeutic approaches based on serine proteases.

Collaborations

Uemura has collaborated with notable colleagues, including Akira Okui and Katsuya Kominami, to further enhance the research and development of serine proteases.

Conclusion

Hidetoshi Uemura's contributions to serine protease research have established him as a key figure in the field. His innovative patents and collaborations continue to influence advancements in biochemistry and pharmaceuticals.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…